The Cardiff, UK-based company's stock surge followed the U.S. FDA granting its treatment eRapa a Fast Track designation. The drug, a proprietary encapsulated form of rapamycin, is being developed for ...
Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous PolyposisUnderscores unmet need for a ...
Biodexa (NASDAQ:BDRX) stock soared 76% in morning trading after the company announced it has received FDA Fast Track designation for its drug eRapa for the treatment of familial adenomatous polyposis, ...
The U.K. biopharmaceutical company said data from a Phase 2 study of eRapa, a treatment for familial adenomatous polyposis, showed the drug to be safe and well-tolerated among users. The treatment ...